Can a small band of biopharma players succeed where Eli Lilly failed? They’re taking a shot
Eli Lilly didn’t try to spin anything about the mid-stage data they got on their CHK1/CHK2 drug prexasertib for ovarian cancer patients. The drug failed to move the dial in a significant fashion and they unceremoniously swept it right out of the pipeline a little more than 2 years ago.
Usually, that would have been it, another once-promising drug that didn’t make the cut. We see it regularly. But a small group of biotech players has come together to take another crack at a pivotal play on this drug. And they believe they have the key to making a success of it.